1. Scrip

AbbVie Adds IBD Candidate In Deal With China’s FutureGen

 
• By Joseph Haas

Deal snapshot: AbbVie joins peers Merck & Co., Roche and Pfizer with a TL1A-targeted antibody for potential therapy in inflammatory bowel disease, paying $150m up front.

Next gen
FutureGen's bispecific might offer better efficacy, less frequent dosing • Source: Shutterstock

Who: AbbVie/FutureGen

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business